Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glyn Lewis

Showing results (431-440 of 494) with videos related to

Pageof 50
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 29, 2020
Cost-Effectiveness of Different Formats for Delivery of Cognitive Behavioral Therapy for Depression: A Systematic Review Based Economic ModelQi Wu, Jinshuo Li, Steve Parrott, et al.
Brain : a Journal of Neurology|September 18, 2025
Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardationIan Lam Leong, Tsz Huen Ng, Kunal Sen, et al.
BMJ (Clinical Research Ed.)|August 21, 2013
Clinical effectiveness of collaborative care for depression in UK primary care (CADET): cluster randomised controlled trialDavid A Richards, Jacqueline J Hill, Linda Gask, et al.
Journal of Psychopharmacology (Oxford, England)|January 14, 2014
Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) studyKaren Hodgson, Rudolf Uher, Andrew A Crawford, et al.
Journal of Personalized Medicine|December 24, 2021
A Patient Stratification Approach to Identifying the Likelihood of Continued Chronic Depression and Relapse Following Treatment for DepressionRob Saunders, Zachary D Cohen, Gareth Ambler, et al.
JAMA Psychiatry|January 29, 2016
Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General PopulationHannah J Jones, Evie Stergiakouli, Katherine E Tansey, et al.
BMC Psychiatry|March 16, 2022
An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disordersNadia E Crellin, Stefan Priebe, Nicola Morant, et al.
Plos One|August 15, 2014
Cost-effectiveness of collaborative care for depression in UK primary care: economic evaluation of a randomised controlled trial (CADET)Colin Green, David A Richards, Jacqueline J Hill, et al.
Psychological Medicine|February 9, 2022
Catatonia: demographic, clinical and laboratory associationsJonathan P Rogers, Thomas A Pollak, Nazifa Begum, et al.
Biological Psychiatry|March 18, 2019
Integrated Lipidomics and Proteomics Point to Early Blood-Based Changes in Childhood Preceding Later Development of Psychotic Experiences: Evidence From the Avon Longitudinal Study of Parents and ChildrenFrancisco Madrid-Gambin, Melanie Föcking, Sophie Sabherwal, et al.
Pageof 50

Showing results (431-440 of 494) with videos related to

Sort By:
Pageof 50
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 29, 2020
Cost-Effectiveness of Different Formats for Delivery of Cognitive Behavioral Therapy for Depression: A Systematic Review Based Economic ModelQi Wu, Jinshuo Li, Steve Parrott, et al.
Brain : a Journal of Neurology|September 18, 2025
Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardationIan Lam Leong, Tsz Huen Ng, Kunal Sen, et al.
BMJ (Clinical Research Ed.)|August 21, 2013
Clinical effectiveness of collaborative care for depression in UK primary care (CADET): cluster randomised controlled trialDavid A Richards, Jacqueline J Hill, Linda Gask, et al.
Journal of Psychopharmacology (Oxford, England)|January 14, 2014
Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) studyKaren Hodgson, Rudolf Uher, Andrew A Crawford, et al.
Journal of Personalized Medicine|December 24, 2021
A Patient Stratification Approach to Identifying the Likelihood of Continued Chronic Depression and Relapse Following Treatment for DepressionRob Saunders, Zachary D Cohen, Gareth Ambler, et al.
JAMA Psychiatry|January 29, 2016
Phenotypic Manifestation of Genetic Risk for Schizophrenia During Adolescence in the General PopulationHannah J Jones, Evie Stergiakouli, Katherine E Tansey, et al.
BMC Psychiatry|March 16, 2022
An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disordersNadia E Crellin, Stefan Priebe, Nicola Morant, et al.
Plos One|August 15, 2014
Cost-effectiveness of collaborative care for depression in UK primary care: economic evaluation of a randomised controlled trial (CADET)Colin Green, David A Richards, Jacqueline J Hill, et al.
Psychological Medicine|February 9, 2022
Catatonia: demographic, clinical and laboratory associationsJonathan P Rogers, Thomas A Pollak, Nazifa Begum, et al.
Biological Psychiatry|March 18, 2019
Integrated Lipidomics and Proteomics Point to Early Blood-Based Changes in Childhood Preceding Later Development of Psychotic Experiences: Evidence From the Avon Longitudinal Study of Parents and ChildrenFrancisco Madrid-Gambin, Melanie Föcking, Sophie Sabherwal, et al.
Pageof 50